UBS Upgrades Sarepta Therapeutics (SRPT) to Buy on expected accelerated approval for '9001
Tweet Send to a Friend
(Updated - December 16, 2022 8:37 AM EST)
UBS analyst Colin Bristow upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst Colin Bristow upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
